Protara Secures $75 Million Funding to Support TARA-002 and Expand Pipeline Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 05 2025
0mins
Source: NASDAQ.COM
Stock Performance: Protara Therapeutics Inc. (TARA) shares fell over 18% to $5.55 in premarket trading following the announcement of a $75 million public offering of 13 million shares at $5.75 each.
Offering Details: The underwriters have a 30-day option to purchase an additional 1.95 million shares, with the offering expected to close around December 8, 2025, subject to customary conditions.
Use of Proceeds: The net proceeds from the offering will support the clinical development of TARA-002, an investigational cell therapy for non-muscle invasive bladder cancer and lymphatic malformations, as well as other clinical initiatives and general corporate purposes.
Current Trials and Designations: TARA-002 is in a Phase 2 trial for pediatric lymphatic malformations and has received Rare Pediatric Disease and Orphan Drug designations, while Protara is also advancing IV Choline Chloride, which has similar designations from the FDA.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like TARA with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on TARA
Wall Street analysts forecast TARA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TARA is 24.83 USD with a low forecast of 21.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.170
Low
21.00
Averages
24.83
High
30.00
Current: 7.170
Low
21.00
Averages
24.83
High
30.00
About TARA
Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ScinoPharm Secures FDA Approval for Glatiramer Acetate Injection in Multiple Sclerosis
- FDA Approval: ScinoPharm Taiwan (TWSE:1789) received FDA approval for its Glatiramer Acetate Injection for treating adult multiple sclerosis patients, marking the company's first finished drug approval and paving the way for regulatory submissions in Europe and Asia for broader commercialization.
- Market Reaction: Following this announcement, ScinoPharm's stock price rose by 3.08% to NT$23.40 on January 8, 2025, reflecting positive market sentiment regarding the product's prospects.
- Clinical Trial Progress: The approval supports the company's competitiveness in the global market, as Glatiramer Acetate remains a key product despite revenue erosion from generics, highlighting its ongoing relevance in the biotech sector.
- Strategic Positioning: This approval not only strengthens ScinoPharm's position in the biopharmaceutical landscape but also lays the groundwork for future market expansions, demonstrating the company's commitment to innovative drug development.
Continue Reading
Protara Doses First Patient in Pivotal THRIVE-3 Trial for IV Choline Chloride
- Trial Initiation: Protara Therapeutics has dosed the first patient in its pivotal THRIVE-3 trial for intravenous Choline Chloride, aiming to become the first FDA-approved treatment for choline deficiency in patients reliant on long-term parenteral support, addressing a significant market gap.
- Patient Enrollment: The study plans to enroll approximately 105 patients to assess the efficacy and safety of low- and high-dose IV Choline Chloride, which is expected to significantly reduce the risks of hepatic injury and neuropsychological impairment faced by nearly 78% of long-term parenteral support patients.
- Regulatory Progress: IV Choline Chloride has received Fast Track and Orphan Drug Designation from the FDA, underscoring its potential in treating this underserved population, with interim analysis results anticipated in the second half of 2026.
- Market Performance: Protara's stock is currently trading at $5.46, reflecting a 6.42% increase from its 52-week low of $2.77, indicating positive market expectations and increased investor confidence in the new therapy.
Continue Reading